KFG Wealth Management LLC Sells 321 Shares of Novo Nordisk A/S (NYSE:NVO)

KFG Wealth Management LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,854 shares of the company’s stock after selling 321 shares during the period. KFG Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $502,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $29,000. Tower Research Capital LLC TRC increased its position in shares of Novo Nordisk A/S by 165.3% during the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after purchasing an additional 124 shares during the period. Pacific Center for Financial Services increased its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Finally, Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded down $0.05 on Friday, reaching $122.70. The company’s stock had a trading volume of 5,181,119 shares, compared to its average volume of 4,882,816. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The company has a market cap of $550.62 billion, a price-to-earnings ratio of 45.55, a PEG ratio of 2.08 and a beta of 0.41. The business’s fifty day moving average price is $126.36 and its 200 day moving average price is $110.50. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NVO shares. BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Finally, UBS Group started coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.